Protocol Ledger

NCT04603937 · Phase III · TERMINATED

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Interventional Phase III clinical trial protocol NCT04603937 sponsored by Kodiak Sciences in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-30 Enrollment: 459 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04603937
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)459 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04603937
Protocol FieldVerified Registry Value
NCT IdentifierNCT04603937
Consolidated Lead SponsorKodiak Sciences
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment459 participants (ACTUAL)
Registered Start Date2020-09-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04603937
Hospital Research SiteLocationSite Profile
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI